干扰素-ω的研究进展

Progress in research on interferon-ω

自1985年以来,在许多动物体内都已鉴定出含有干扰素ω（interferon,IFN-ω）,它是一种I型IFN,但是在犬科动物和小鼠体内却没有。IFN-ω具有与IFN-α类似的抗病毒、抗增殖和抗肿瘤活性的作用。迄今为止,IFN-ω已被选作参与治疗人类和其他动物的一些疾病或病毒感染。研究表明人类IFN-ω在人癌细胞的某些模型中表现出的抗肿瘤活性,可用于这些疾病的诊断。重组猫IFN-ω已经在一些国家获得了治疗犬细小病毒、猫白血病病毒和猫免疫缺陷病毒感染的许可。另外,当用于治疗其他病毒感染或疾病时,它也表现出了一定的作用。本文综述了IFN-ω的已知生物学活性及其临床应用,为IFN-ω作为临床治疗药物的进一步研究提供参考。

Since 1985,interferon-ω（IFN-ω）,a type I IFN has been identified in many animals except canines and mice. IFN-ω has similar antiviral,anti-proliferative and antitumor activities as IFN-α does. To date,IFN-ω has been chosen in treatment of some diseases or viral infections in humans and other animals. Studies have shown that human IFN-ω exhibits antitumor activity in certain models of human cancer cells and can be used in the diagnosis of these diseases. Recombinant cat IFN-ω has been licensed in some countries for treatment of canine parvovirus,feline leukemia virus and feline immunodeficiency virus infections. In addition,this inferon also plays a role when used to treat other viral infections or diseases. This review discusses the known biological activity of IFN-ω and its clinical application. We anticipate that the information provided in this review will facilitate further research on IFN-ω as a clinical therapeutic drug.